Keck School of Medicine of USC

Event

8th Annual USC Multidisciplinary Breast Cancer Symposium

presented by Keck School of Medicine of USC

13 others would like to attend.

Register Now

Notification icon Saturday, January 23, 2021 7:30 AM - 3 PM America/Los_Angeles

Event info

REGISTER HERE.

This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include genetics, diagnostic imaging, pathology, surgical oncology, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.

The management of genetic risk will be presented, as the importance of pathogenic mutations and variants of uncertain significance have become more integral in treatment decisions. The use of MRI as a diagnostic tool for patients having neoadjuvant chemotherapy will be reinforced using data from the University of Southern California. Recent advances in oncoplastic surgery will be presented by one of the surgeons who developed the field. The radiation oncology topic covers the advances in partial breast and accelerated radiation techniques.

The understanding of the HER2 receptor continues to evolve, and the biology of the HER2 axis will be presented by one of the pioneers in our understanding of this phenomenon. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the emergence of resistance to antiestrogen therapy, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer.

EDUCATIONAL OBJECTIVES

  1. Assess the evolution of recent concepts of genetic risk for breast cancer.
  2. Outline the role of diagnostic MRI in neoadjuvant treatment.
  3. Evaluate patients as candidates for oncoplastic surgical procedures.
  4. Outline the biology of the HER2 axis and its role in treating metastatic cancer.
  5. Describe the role of CDK inhibitors in treating ER+ cancers.
  6. Review newer concepts in treatment of triple negative breast cancers, including immunotherapy.
  7. Describe the evolving role of radiation therapy to the breast and axilla, such as changes in dose/fractionation and technique.

ACCREDITATION

The Keck School of Medicine of the University of Southern California designates this Live Activity activity for a maximum of 6.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.

Course Syllabus

Click HERE to view the syllabus

13 others would like to attend.

Register Now


0 Comments
Login to view comments. Click here to Login